< Zurück zu den aktuellen Neuigkeiten & Events

Veranstaltungen

Webinar: Patent eligibility of AI-related pharmaceutical inventions and practical tips for its patent obtainment in Japan

November 2021

Veranstaltungsdatum: 1. Dezember 2021

Join our webinar on 1st December, where speakers from Shiga, one of the leading IP firms in Japan, will present on ‚Patent eligibility of AI-related pharmaceutical inventions and practical tips for its patent obtainment in Japan‘.

About the webinar

Digital transformation has been reshaping the pharmaceutical industry. Today, AI has helped explore novel uses of existing drugs, develop new drugs, and accelerate R&D activity in the industry.

In Japan, patent eligibility of AI-related inventions is less strict than that in EP practice. When AI has been applied to pharmaceuticals, issues on inventive step, support requirements, and enable requirements often arise as points to be overcome.

Our speakers will explain patent eligibility on combinations of AI and pharmaceutical inventions, suggesting some practical points of the JPO Examination Guidelines. They will then give listeners insight into some case examples of AI-related pharmaceutical patents in Japan.

Watch the webinar: 

Speakers

Dr. Masato Iida, Shiga

Fumio Takahashi, Shiga

Aktuelle Neuigkeiten

Event - 12. September 2025

Wolters Kluwer Breakfast Panel on AI & IP at AIPPI

Sofie McPherson, Patent Director at HGF, will be moderating a special breakfast panel session hosted by Wolters Kluwer at the AIPPI World Congress in Yokohama on 15 September 2025. Session …

Veranstaltungsdetails

T1465/23 – No Narrowing by Description—EPO Board Terminates Inventive Step Analysis for Arbitrary Modifications Citing G1/24 and G1/19

“The potential patentability of a specific narrow embodiment…cannot render a claim allowable which, due to its breadth, encompasses a multitude of other, non-inventive embodiments” – r. 3.5. Background EP3113515 was …

Weiterlesen

Wrestling with G1/24 – How should the claims be interpreted in view of the description?

In G1/24, the Enlarged Board of Appeal (EBA) codified how claims should be interpreted for assessing patentability: in consultation with the description. However, the decision was light on how, in …

Weiterlesen

Welcome to HGF Presents - New Video Series

Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …

Weiterlesen

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Weiterlesen

PRESSEMITTEILUNG HGF stärkt seine Präsenz in Europa mit drei neuen Partnern in Frankreich und Deutschland

HGF stärkt seine Präsenz in Europa mit drei neuen Partnern in Frankreich und Deutschland HGF freut sich, die Aufnahme von drei neuen Partnern bekannt zu geben, die die Präsenz des …

Weiterlesen

Providing Enabling Disclosure for AI inventions at the EPO

  Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …

Weiterlesen

Personalised Medicine Patenting of Known Drugs for Known Indications at the EPO

Video overview: The identification of specific sub-groups of patients to treat with a known drug, even if said patients may have been treated before with the drug, can yield patentable …

Weiterlesen
Alle Neuigkeiten anzeigen